M.D. Peled to market Universal Detection Technology's Bio-Weapon Detection Systems in Israel

Universal Detection Technology (http://www.udetection.com) (OTCBB:UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, announced today that it has received its first purchase order from the Company’s newly signed Israeli Distributor, M.D. Paled.

Under the new agreement, M.D. Peled will market and distribute Universal Detection Technology's Bio-Weapon Detection Systems to government and private sector users in Israel.

"Clearly, the threat of Biological weapons is an international issue as evidenced by the United Nations Security Council Meeting and passing of Resolution 1887. The resolution strengthens implementation for resolution 1540 which requires governments to establish domestic controls to prevent the proliferation of nuclear, chemical, or biological weapons and their means of delivery," said Jacques Tizabi, CEO of Universal Detection Technology. "UNDT’s Biological Weapons Detection Systems are being used right now by the US Army, defense contractors and first responders,” said Tizabi.

The initial order is for UNDT’s five agent handheld biodetection kits, which recently received certification by the Department of Homeland Security under the SAFETY Act.

Universal Detection Technology recently showcased its TS-10-5-agent biodetection kit at ASIS International 2009 in Anaheim, California earlier this month.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer